Total Hip ArthroplastyNCT04145921
Effectiveness of Fast-track Clinical Pathway on Minimally-invasive Total Hip Arthroplasty Surgery in NTUH
A study testing ERAS for MIS-THA and conventional MIS-THA in people with Total Hip Arthroplasty, run by National Taiwan University Hospital.
Trial summary
The objective of this study was to evaluate the effects of an enhanced recovery after surgery (ERAS) pathway incorporated with pre-operative physical therapy and education on immediate and short-term outcomes of minimally-invasive surgery of total hip arthroplasty (MIS-THA). Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Total Hip Arthroplasty
- What is being tested?
- ERAS for MIS-THA and conventional MIS-THA
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 75 participants
- Where
- No sites listed yet
- Study dates
- 7 Jan 2014to 28 Aug 2018
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- patients with advanced osteonecrosis of femoral head or hip osteoarthritis receiving unilateral primary minimally-invasive surgery of total hip arthroplasty (MIS-THA) performed by the same surgeon at the same hospital
Who cannot join
- patients with renal or hepatic function impairment which precluded multimodal pain control
About this study
The objective of this study was to evaluate the effects of an enhanced recovery after surgery (ERAS) pathway incorporated with pre-operative physical therapy and education on immediate and short-term outcomes of minimally-invasive surgery of total hip arthroplasty (MIS-THA). We hypothesized that this ERAS pathway can shorten post-operative length of hospital stay and ensure same-day independent mobilization in MIS-THA. The first specific aim was to compare primary immediate outcomes, including post-operative length of hospital stay and the rate of same-day independent mobilization, between ERAS for MIS-THA patients and conventional MIS-THA patients. The second aim was to compare other immediate outcomes, including post-operative pain scores, analgesics usage, the rate of blood transfusion and post-operative nausea and vomiting (PONV), between the two groups of patients. Third, we aimed to compare short-term outcomes, including post-operative 1-year Harris hip score, Oxford hip score and EQ-5D index of quality of life, between the two groups of patients. We also compared hospital cost and profit between the two groups of patients. Moreover, we identified the factors affecting post-operative length of hospital stay in ERAS for MIS-THA patients.
Read the detailed description
Study subjects:
We conducted a prospective comparative study to investigate 50 patients receiving an ERAS pathway incorporated with pre-operative physical therapy and education for MIS-THA and 25 patients receiving conventional MIS-THA. We included the patients with advanced osteonecrosis of femoral head or hip osteoarthritis receiving unilateral primary MIS-THA performed by the same surgeon at the same hospital. We excluded patients with renal or hepatic function impairment which precluded multimodal pain control. However, we did not preselect patients with younger age or better activity level. This study was approved by the Institutional Review Board at National Taiwan University Hospital. Written informed consent was obtained from all patients.
ERAS for MIS-THA versus conventional MIS-THA:
In this study, ERAS for MIS-THA was defined as the ERAS pathway incorporated with pre-operative short-term physical therapy and education for MIS-THA. On the other hand, conventional MIS-THA in this study was defined as the conventional pathway without pre-operative physical therapy and education for MIS-THA. Both of ERAS for MIS-THA and conventional MIS-THA comprised the same MIS-THA techniques, multimodal pain control, standardized volume management and PONV prophylaxis, deep vein thrombosis prophylaxis and post-operative rehabilitation program.
Pre-operative physical therapy and education:
Pre-operatively in the outpatient clinics, we informed patients that the discharge days depended on the rehabilitation progress by oral and written information. We also gave patients the detailed information about rehabilitation program and discharge criteria. We consulted physical therapy specialists for one session of physical therapy intervention before operation. The standardized pre-operative physical therapy programs included three parts. First, posterior dislocation precautions were well explained to the patients, including no hip flexion greater than 90 degrees, no hip adduction or hip internal rotation beyond neutral, and no combination of the above motions. Then, therapeutic exercise programs given in acute post-operative inpatient phase were demonstrated and practiced, including ankle pumps, quadriceps sets, gluteal sets, bed-supported knee bends, active hip abduction, and straight leg raising. The patients were instructed to do these exercises by themselves at home until the day of operation. Last, the patients received activity and functional training, including bed mobility, transfer skills, gait training with appropriate assistive device and weight bearing to tolerance, stair training, and modified activities of daily living following precautions.
MIS-THA techniques:
We utilized posterolateral mini-incision techniques with posterior capsulotendinous repair to the posterolateral aspect of greater trochanter bone for every patient receiving MIS-THA. The incision size was routinely 5-8 cm with hip in flexion position based on body build. We did not use surgical drains.
Multimodal pain control:
For post-operative analgesia, we used multimodal pain control protocols including pre-emptive oral analgesics (acetaminophen, celecoxib, tramadol, gabapentin), intra-operative periarticular injection with cocktail mix of analgesics and antibiotics (levobupivacaine, ketorolac, epinephrine, cefazolin), post-operative oral analgesics (acetaminophen, celecoxib, tramadol, gabapentin), and intramuscular ketorolac as needed to control pain without reliance on morphine. Levobupivacaine used in our periarticular injection is a safer analgesic compared with bupivacaine in terms of cardiovascular adverse effects. We did not routinely use patient-controlled analgesia (PCA) pumps containing morphine unless there was a request from the patient.
Standardized volume management and PONV prophylaxis:
For standardized volume management, we used tetrastarch colloid solutions and restrictive strategy of allogenic blood transfusion (hemoglobin < 9 g/dl with altered vital signs or hemoglobin < 7 g/dl without altered vital signs). For PONV prophylaxis and treatment, we used esomeprazole, metoclopramide, ondansetron, and normovolemic fluid control with tetrastarch colloid solutions.
Deep vein thrombosis prophylaxis:
For deep vein thrombosis prophylaxis, we used anti-embolism stockings and daily enoxaparin (40mg) starting from 12 hours after operation for 2 days then oral aspirin for 6 weeks. We used a short-duration anti-thrombotic agent combined with aspirin and early mobilization because the risk of deep vein thrombosis after THA with short-duration pharmacological prophylaxis and early mobilization was quite low. Besides, Asians have a 70% lower prevalence of venous thromboembolism compared to Caucasians.
Post-operative rehabilitation program:
Post-operative rehabilitation program was the same as pre-operative physical therapy and was conducted with close observation of patient's pain tolerance and general conditioning. All patients were discharged direct to their residences without any home-care rehabilitation service.
Discharge criteria:
For ERAS for MIS-THA patients and conventional MIS-THA patients, we used uniform discharge criteria including being self-dependent, being able to walk with crutches or walkers, sufficient pain control with oral analgesics, no infection signs, well knowledge of position restriction, and being able to perform home exercise.
Outcome measures:
A database was established for prospective collection of patient demographic, pre- and post-operative data for statistical analysis. The evaluator was blinded to the grouping of patients in data collection. Primary immediate outcomes were post-operative length of hospital stay and the rate of same-day independent mobilization (ambulation without assistance from another person within 24 hours after operation). Other immediate outcomes included post-operative visual analog scale (VAS) pain scores, analgesics usage, the rate of blood transfusion and PONV. Short-term outcomes were post-operative 1-year Harris hip score, Oxford hip score, and EQ-5D index of self-reported health-related quality of life. We also recorded adverse events as well as hospital cost and profit.
Statistical analysis:
A priori sample size determination was based on post-operative length of hospital stay, which was the primary outcome measure. The sample size was calculated to detect a mean difference of 3 days in post-operative length of stay between ERAS for MIS-THA patients and conventional MIS-THA patients assuming a standard deviation of 3.5 days. We assumed a two-sided type I error of 0.05 and a power of 80%. This resulted in a required sample size of 22 in each group. In this study, we included 50 patients in ERAS group and 25 patients in conventional group, respectively. The case number in this study was sufficient for a priori sample size calculation.
Data are presented as mean ± standard deviation and ratio. Student t-test, Mann-Whitney U test, Chi-square test and Fisher exact test were used to compare continuous or categorical variables between different groups of subjects. Multivariable regression analysis by best subset regression was used to identify significant variables affecting post-operative length of hospital stay. Longitudinal analysis by Generalized Estimating Equations (GEE) using robust standard errors was used to compare repeated measurements such as post-operative VAS pain scores. STATA 11 statistical software (StataCorp LP, College Station, TX, USA) was used for statistical analysis. A two-tailed p value of < 0.05 was considered statistically significant.
- Conditions
- Total Hip Arthroplasty
- Being tested
- ERAS for MIS-THA, conventional MIS-THA
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ERAS for MIS-THAProcedure or surgery
enhanced recovery after surgery (ERAS) pathway for minimally-invasive surgery of total hip arthroplasty (MIS-THA)
conventional MIS-THAProcedure or surgery
conventional pathway for minimally-invasive surgery of total hip arthroplasty (MIS-THA)
| Study group | Role | What they receive |
|---|---|---|
| ERAS for MIS-THA | Experimental | enhanced recovery after surgery (ERAS) pathway for minimally-invasive surgery of total hip arthroplasty (MIS-THA) Receives: Procedure: ERAS for MIS-THA |
| conventional MIS-THA | Active comparator | conventional pathway for minimally-invasive surgery of total hip arthroplasty (MIS-THA) Receives: Procedure: conventional MIS-THA |
What is being measured
The primary outcome is the main question the study is designed to answer.
post-operative length of hospital stay
post-operative length of hospital stay
Measured: up to 2 weeks after operation
rate of same-day independent mobilization
rate of same-day independent mobilization (ambulation without assistance from another person within 24 hours after operation)
Measured: up to 24 hours after operation
Secondary outcomes (7)
post-operative VAS pain scores
post-operative visual analog scale (VAS) pain scores
Measured: up to 24 hours after operation
post-operative analgesics usage
post-operative analgesics usage
Measured: up to 2 weeks after operation
the rate of blood transfusion
the rate of blood transfusion
Measured: up to 2 weeks after operation
rate of PONV
rate of post-operative nausea and vomiting (PONV)
Measured: up to 2 weeks after operation
post-operative 1-year Harris hip score
post-operative 1-year Harris hip score
Measured: 1 year after operation
post-operative 1-year Oxford hip score
post-operative 1-year Oxford hip score
Measured: 1 year after operation
post-operative 1-year EQ-5D index of quality of life
post-operative 1-year EQ-5D index of self-reported health-related quality of life
Measured: 1 year after operation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Oct 2019
- Study start7 Jan 2014
- Primary completion28 Jun 2016
- Study completion28 Aug 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Total Hip ArthroplastyStudies of the same condition, open and under way.
- More trials run by National Taiwan University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 75 participants (actual)
Sponsor and investigators
- Lead sponsor
- National Taiwan University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Chen-Ti Wang, MD,PhD, Principal investigator, National Taiwan University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04145921
- Sponsor's protocol ID
- 201207008RIC
- Status last verified
- Oct 2019
- First submitted
- 29 Oct 2019
- Last updated
- 31 Oct 2019
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 31 Oct 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effectiveness of Fast-track Clinical Pathway on Minimally-invasive Total Hip Arthroplasty Surgery in NTUH
- ClinicalTrials.gov ID
- NCT04145921
- Acronym / sponsor ID
- 201207008RIC
- Conditions
- Total Hip Arthroplasty
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 75 participants (actual)
- Lead sponsor
- National Taiwan University HospitalUniversity, hospital or other
- Study start
- 7 Jan 2014 (actual)
- Primary completion
- 28 Jun 2016 (actual)
- Study completion
- 28 Aug 2018 (actual)
- First posted
- 31 Oct 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this study was to evaluate the effects of an enhanced recovery after surgery (ERAS) pathway incorporated with pre-operative physical therapy and education on immediate and short-term outcomes of minimally-invasive surgery of total hip arthroplasty (MIS-THA). We hypothesized that this ERAS pathway can shorten post-operative length of hospital stay and ensure same-day independent mobilization in MIS-THA. The first specific aim was to compare primary immediate outcomes, including post-operative length of hospital stay and the rate of same-day independent mobilization, between ERAS for MIS-THA patients and conventional MIS-THA patients. The second aim was to compare other immediate outcomes, including post-operative pain scores, analgesics usage, the rate of blood transfusion and post-operative nausea and vomiting (PONV), between the two groups of patients. Third, we aimed to compare short-term outcomes, including post-operative 1-year Harris hip score, Oxford hip score and EQ-5D index of quality of life, between the two groups of patients. We also compared hospital cost and profit between the two groups of patients. Moreover, we identified the factors affecting post-operative length of hospital stay in ERAS for MIS-THA patients.
Detailed description
Study subjects:
We conducted a prospective comparative study to investigate 50 patients receiving an ERAS pathway incorporated with pre-operative physical therapy and education for MIS-THA and 25 patients receiving conventional MIS-THA. We included the patients with advanced osteonecrosis of femoral head or hip osteoarthritis receiving unilateral primary MIS-THA performed by the same surgeon at the same hospital. We excluded patients with renal or hepatic function impairment which precluded multimodal pain control. However, we did not preselect patients with younger age or better activity level. This study was approved by the Institutional Review Board at National Taiwan University Hospital. Written informed consent was obtained from all patients.
ERAS for MIS-THA versus conventional MIS-THA:
In this study, ERAS for MIS-THA was defined as the ERAS pathway incorporated with pre-operative short-term physical therapy and education for MIS-THA. On the other hand, conventional MIS-THA in this study was defined as the conventional pathway without pre-operative physical therapy and education for MIS-THA. Both of ERAS for MIS-THA and conventional MIS-THA comprised the same MIS-THA techniques, multimodal pain control, standardized volume management and PONV prophylaxis, deep vein thrombosis prophylaxis and post-operative rehabilitation program.
Pre-operative physical therapy and education:
Pre-operatively in the outpatient clinics, we informed patients that the discharge days depended on the rehabilitation progress by oral and written information. We also gave patients the detailed information about rehabilitation program and discharge criteria. We consulted physical therapy specialists for one session of physical therapy intervention before operation. The standardized pre-operative physical therapy programs included three parts. First, posterior dislocation precautions were well explained to the patients, including no hip flexion greater than 90 degrees, no hip adduction or hip internal rotation beyond neutral, and no combination of the above motions. Then, therapeutic exercise programs given in acute post-operative inpatient phase were demonstrated and practiced, including ankle pumps, quadriceps sets, gluteal sets, bed-supported knee bends, active hip abduction, and straight leg raising. The patients were instructed to do these exercises by themselves at home until the day of operation. Last, the patients received activity and functional training, including bed mobility, transfer skills, gait training with appropriate assistive device and weight bearing to tolerance, stair training, and modified activities of daily living following precautions.
MIS-THA techniques:
We utilized posterolateral mini-incision techniques with posterior capsulotendinous repair to the posterolateral aspect of greater trochanter bone for every patient receiving MIS-THA. The incision size was routinely 5-8 cm with hip in flexion position based on body build. We did not use surgical drains.
Multimodal pain control:
For post-operative analgesia, we used multimodal pain control protocols including pre-emptive oral analgesics (acetaminophen, celecoxib, tramadol, gabapentin), intra-operative periarticular injection with cocktail mix of analgesics and antibiotics (levobupivacaine, ketorolac, epinephrine, cefazolin), post-operative oral analgesics (acetaminophen, celecoxib, tramadol, gabapentin), and intramuscular ketorolac as needed to control pain without reliance on morphine. Levobupivacaine used in our periarticular injection is a safer analgesic compared with bupivacaine in terms of cardiovascular adverse effects. We did not routinely use patient-controlled analgesia (PCA) pumps containing morphine unless there was a request from the patient.
Standardized volume management and PONV prophylaxis:
For standardized volume management, we used tetrastarch colloid solutions and restrictive strategy of allogenic blood transfusion (hemoglobin < 9 g/dl with altered vital signs or hemoglobin < 7 g/dl without altered vital signs). For PONV prophylaxis and treatment, we used esomeprazole, metoclopramide, ondansetron, and normovolemic fluid control with tetrastarch colloid solutions.
Deep vein thrombosis prophylaxis:
For deep vein thrombosis prophylaxis, we used anti-embolism stockings and daily enoxaparin (40mg) starting from 12 hours after operation for 2 days then oral aspirin for 6 weeks. We used a short-duration anti-thrombotic agent combined with aspirin and early mobilization because the risk of deep vein thrombosis after THA with short-duration pharmacological prophylaxis and early mobilization was quite low. Besides, Asians have a 70% lower prevalence of venous thromboembolism compared to Caucasians.
Post-operative rehabilitation program:
Post-operative rehabilitation program was the same as pre-operative physical therapy and was conducted with close observation of patient's pain tolerance and general conditioning. All patients were discharged direct to their residences without any home-care rehabilitation service.
Discharge criteria:
For ERAS for MIS-THA patients and conventional MIS-THA patients, we used uniform discharge criteria including being self-dependent, being able to walk with crutches or walkers, sufficient pain control with oral analgesics, no infection signs, well knowledge of position restriction, and being able to perform home exercise.
Outcome measures:
A database was established for prospective collection of patient demographic, pre- and post-operative data for statistical analysis. The evaluator was blinded to the grouping of patients in data collection. Primary immediate outcomes were post-operative length of hospital stay and the rate of same-day independent mobilization (ambulation without assistance from another person within 24 hours after operation). Other immediate outcomes included post-operative visual analog scale (VAS) pain scores, analgesics usage, the rate of blood transfusion and PONV. Short-term outcomes were post-operative 1-year Harris hip score, Oxford hip score, and EQ-5D index of self-reported health-related quality of life. We also recorded adverse events as well as hospital cost and profit.
Statistical analysis:
A priori sample size determination was based on post-operative length of hospital stay, which was the primary outcome measure. The sample size was calculated to detect a mean difference of 3 days in post-operative length of stay between ERAS for MIS-THA patients and conventional MIS-THA patients assuming a standard deviation of 3.5 days. We assumed a two-sided type I error of 0.05 and a power of 80%. This resulted in a required sample size of 22 in each group. In this study, we included 50 patients in ERAS group and 25 patients in conventional group, respectively. The case number in this study was sufficient for a priori sample size calculation.
Data are presented as mean ± standard deviation and ratio. Student t-test, Mann-Whitney U test, Chi-square test and Fisher exact test were used to compare continuous or categorical variables between different groups of subjects. Multivariable regression analysis by best subset regression was used to identify significant variables affecting post-operative length of hospital stay. Longitudinal analysis by Generalized Estimating Equations (GEE) using robust standard errors was used to compare repeated measurements such as post-operative VAS pain scores. STATA 11 statistical software (StataCorp LP, College Station, TX, USA) was used for statistical analysis. A two-tailed p value of < 0.05 was considered statistically significant.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| ERAS for MIS-THA | Experimental | Procedure: ERAS for MIS-THAenhanced recovery after surgery (ERAS) pathway for minimally-invasive surgery of total hip arthroplasty (MIS-THA) |
| conventional MIS-THA | Active comparator | Procedure: conventional MIS-THAconventional pathway for minimally-invasive surgery of total hip arthroplasty (MIS-THA) |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (1 listed)
- patients with advanced osteonecrosis of femoral head or hip osteoarthritis receiving unilateral primary minimally-invasive surgery of total hip arthroplasty (MIS-THA) performed by the same surgeon at the same hospital
Key exclusion criteria (1 listed)
- patients with renal or hepatic function impairment which precluded multimodal pain control
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ERAS for MIS-THAenhanced recovery after surgery (ERAS) pathway for minimally-invasive surgery of total hip arthroplasty (MIS-THA) | Procedure or surgery | ERAS for MIS-THA |
| conventional MIS-THAconventional pathway for minimally-invasive surgery of total hip arthroplasty (MIS-THA) | Procedure or surgery | conventional MIS-THA |
Primary outcome
post-operative length of hospital stay
Time frame: up to 2 weeks after operation
post-operative length of hospital stay
rate of same-day independent mobilization
Time frame: up to 24 hours after operation
rate of same-day independent mobilization (ambulation without assistance from another person within 24 hours after operation)
7 secondary outcomes
post-operative VAS pain scores
Time frame: up to 24 hours after operation
post-operative analgesics usage
Time frame: up to 2 weeks after operation
the rate of blood transfusion
Time frame: up to 2 weeks after operation
rate of PONV
Time frame: up to 2 weeks after operation
post-operative 1-year Harris hip score
Time frame: 1 year after operation
post-operative 1-year Oxford hip score
Time frame: 1 year after operation
post-operative 1-year EQ-5D index of quality of life
Time frame: 1 year after operation
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Oct 2019.
- Individual participant dataSharing planned: No
Related trials for Total Hip Arthroplasty
Recruiting
Intravenous Dexamethasone (0 vs 4 vs 8 mg) as an Adjunct to PENG Block for Postoperative Analgesia in Total Hip Arthroplasty
Osteoarthritis, Hip, Hip Osteoarthritis
Recruiting
Comparison of Spinal Anesthesia With Intrathecal Morphine Versus PENG Block With or Without Dexamethasone in Hip Arthroplasty
Arthropathy of Hip, Hip Osteoarthritis
RecruitingPhase 4
PENG vs L-ESPB With S-ESPB for Analgesia in Total Hip Arthroplasty
Hip Osteoarthritis, Hip Arthropathy
Recruiting
Intravenous Dexmedetomidine as a Perioperative Autonomic-Immune Neuromodulator
Hip Osteoarthritis
Not yet recruiting
Effects of Combined Pericapsular Nerve Group (PENG) and Lateral Femoral Cutaneous Nerve (LFCN) Blocks on Anaesthetic Requirements and Electroencephalographic Depth of Anaesthesia During Total Hip Arthroplasty
Total Hip Arthroplasty (THA)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Chen-Ti Wang, MD,PhD principal investigator
National Taiwan University Hospital
Questions about this trial
What is this clinical trial studying?
A study testing ERAS for MIS-THA and conventional MIS-THA in people with Total Hip Arthroplasty, run by National Taiwan University Hospital.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 31 Oct 2019. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
post-operative length of hospital stay (time frame: up to 2 weeks after operation). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Oct 2019.